Genetic Characteristics and Curative Effect Analysis of 81 Patients with Ph Chromosome Positive Acute Lymphoblastic Leukemia

2020 ◽  
Vol 10 (11) ◽  
pp. 2805-2811
Author(s):  
琦 孔
Blood ◽  
1987 ◽  
Vol 70 (5) ◽  
pp. 1458-1461 ◽  
Author(s):  
N Tachibana ◽  
SC Raimondi ◽  
SJ Lauer ◽  
P Sartain ◽  
LW Dow

Children with Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) have a poorer prognosis than do most pediatric patients with ALL. Because of this poor prognosis and the presence of the Ph chromosome, we have asked whether or not Ph + ALL involves a multipotential stem cell. We cultured hematopoietic progenitors from two children with Ph+ ALL and examined individual BFU-E and CFU-GM colonies for the Ph chromosome. We studied cells from two patients after 18 to 34 months of first complete clinical remission; direct cytogenetic analyses showed 26% and 13% Ph+ metaphases in these patients' marrow cells. BFU-E colonies were obtained from light density marrow cells cultured in methylcellulose supplemented with erythropoietin and CFU-GM colonies from agar or methylcellulose cultures stimulated with leukocyte feeder layers. Fifty-seven G-banded metaphases were recovered from 33 colonies. Ten metaphases from seven colonies were Ph+. Ph+ metaphases were found in three of 12 and three of five BFU-E colonies from the two patients. One of 16 CFU-GM colonies from one patient had the Ph+ chromosome; analyzable metaphases were not obtained from CFU-GM of the other patient. No colonies contained both Ph+ and Ph- cells. These results indicate that Ph+ ALL with persistence of Ph+ cells in remission involves a multipotential stem cell for erythroid and granulocyte/macrophage as well as lymphoid lineages. Multipotential stem cell involvement in the pathogenesis of some childhood Ph+ ALL suggests similarities to Ph+ chronic myelocytic leukemia and may contribute to the poor prognosis of these patients.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 163-163 ◽  
Author(s):  
Jose Claudio Rocha ◽  
Cheng Cheng ◽  
Wei Liu ◽  
Shinji Kishi ◽  
Soma Das ◽  
...  

Abstract The acquired genetic characteristics of acute lymphoblastic leukemia (ALL) blasts are often used to guide the intensity of therapy, whereas the germline host genetic characteristics of the patient generally have not been considered. Multiple common, functionally important polymorphisms affect genes whose products determine the pharmacokinetics and pharmacodynamics of antileukemic agents. It is not yet known how genetic polymorphisms may interact to affect the outcome of antileukemic therapy. Combining classification and regression tree with failure time analysis, we assessed whether 16 genetic polymorphisms, alone or in combination, predicted relapses in 246 children with ALL, 116 of whom were treated on the lower-risk (LR) and130 on the higher-risk (HR) arms of the St Jude protocol Total XIIIB. Genotyping was performed for the following polymorphic loci: CYP3A4*1B and CYP3A5*3; GSTP1 313A>G, GSTM1 and GSTT1 deletions; MDR1 exon 21 (2677G>T/A) and MDR1 exon 26 (3435C>T); MTHFR 677C>T and MTHFR 1298A>C; NR3C1 1088A>G; SLC19A1 80G>A; TPMT 238G>C, 460G>A and 719A>G; TYMS enhancer repeat; UGT1A1 promoter repeat polymorphism; VDR intron 8 G>A and VDR FokI (start-site) T>C. In all children with available RNA in their diagnostic ALL blasts, gene expression levels of prognostic genotypes were analyzed using the Affymetrix genechip array HG_U95Av2. Among the HR group, the glutathione S-transferase M1 (GSTM1) non-null genotype was associated with the risk of hematological relapse (5-year cumulative incidence, 17.1%±4.5% compared to 5.1%±2.9% for GSTM1 null genotype, p = 0.03), and among the non-null genotypes, the thymidylate synthetase (TYMS) 3/3 genotype was associated with a further increase in hematologic relapse risk (5-year cumulative incidence, 29.2%±9.5% compared to 10.9%±4.7% for TYMS 2/3 or 2/2 genotypes, p = 0.02). Increased expression levels of these two target genes (p < 0.0001 and p = 0.09, respectively) were consistent with resistance to the drugs interacting with these gene products. For central nervous system relapse, among the HR group, the vitamin D receptor (VDR) start site (p = 0.02) and intron 8 genotypes (p = 0.04) predisposed, whereas for LR patients the TYMS 3/3 genotype predisposed (p = 0.04). The genotypes associated with outcome have pharmacologic plausibility: e.g., high GST activity (GSTM1 non-null) could cause anticancer drug resistance; high TYMS activity (TYMS 3/3) would be less inhibited by antifolates. In conclusion, germline polymorphisms influence the outcome of antileukemic therapy, and therefore represent determinants of response that can be used to optimize therapy.


BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Wencke Walter ◽  
Rabia Shahswar ◽  
Anna Stengel ◽  
Manja Meggendorfer ◽  
Wolfgang Kern ◽  
...  

Abstract Background Considering the clinical and genetic characteristics, acute lymphoblastic leukemia (ALL) is a rather heterogeneous hematological neoplasm for which current standard diagnostics require various analyses encompassing morphology, immunophenotyping, cytogenetics, and molecular analysis of gene fusions and mutations. Hence, it would be desirable to rely on a technique and an analytical workflow that allows the simultaneous analysis and identification of all the genetic alterations in a single approach. Moreover, based on the results with standard methods, a significant amount of patients have no established abnormalities and hence, cannot further be stratified. Methods We performed WTS and WGS in 279 acute lymphoblastic leukemia (ALL) patients (B-cell: n = 211; T-cell: n = 68) to assess the accuracy of WTS, to detect relevant genetic markers, and to classify ALL patients. Results DNA and RNA-based genotyping was used to ensure correct WTS-WGS pairing. Gene expression analysis reliably assigned samples to the B Cell Precursor (BCP)-ALL or the T-ALL group. Subclassification of BCP-ALL samples was done progressively, assessing first the presence of chromosomal rearrangements by the means of fusion detection. Compared to the standard methods, 97% of the recurrent risk-stratifying fusions could be identified by WTS, assigning 76 samples to their respective entities. Additionally, read-through fusions (indicative of CDKN2A and RB1 gene deletions) were recurrently detected in the cohort along with 57 putative novel fusions, with yet untouched diagnostic potentials. Next, copy number variations were inferred from WTS data to identify relevant ploidy groups, classifying an additional of 31 samples. Lastly, gene expression profiling detected a BCR-ABL1-like signature in 27% of the remaining samples. Conclusion As a single assay, WTS allowed a precise genetic classification for the majority of BCP-ALL patients, and is superior to conventional methods in the cases which lack entity defining genetic abnormalities.


Blood ◽  
1993 ◽  
Vol 81 (10) ◽  
pp. 2488-2491 ◽  
Author(s):  
JV Melo ◽  
DE Gordon ◽  
A Tuszynski ◽  
S Dhut ◽  
BD Young ◽  
...  

We have previously shown that the chimeric gene ABL-BCR, formed on the derivative chromosome 9q+ as a result of the t(9;22) translocation, is transcriptionally active in 65% of chronic myeloid leukemia patients. We have now used the same technique, reverse transcription/polymerase chain reaction amplification of ABL-BCR transcripts, to study nine patients with Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL); seven expressed the P190 and two the P210 type of BCR- ABL fusion protein. All seven patients with P190 had ABL-BCR transcripts containing a junction between ABL exon Ib and BCR exon 2 (Ib-e2); in two cases, ABL-BCR transcripts with the Ia-e2 junction type were also present. Of the two P210 ALL patients, one had a Ib-b4 ABL- BCR transcript and the other showed no detectable ABL-BCR expression. Although the BCR-ABL gene is probably fundamental in the pathogenesis of the Ph+ leukemias, differential expression of the ABL-BCR gene could contribute to the biologic heterogeneity of the disease.


2011 ◽  
Vol 29 (5) ◽  
pp. 532-543 ◽  
Author(s):  
Renato Bassan ◽  
Dieter Hoelzer

Although acute lymphoblastic leukemia is curable in one third of adult patients, results vary greatly on account of different clinical, immunologic, and cytogenetic/genetic characteristics. These data, along with the kinetics of response to early treatment, help establish the individual risk class with considerable accuracy, and support risk-specific treatments that should warrant optimal results with as little as possible nonrelapse mortality. Modern first-line therapy consists of standard- and high-dose chemotherapy (increasingly inspired to pediatric principles), hematopoietic stem-cell transplantation, and new targeted therapy, all integrated with the analysis of prognostic factors and the study of subclinical residual disease for key therapeutic decisions. These changes are improving long-term outcome, which in ongoing studies is expected close to 50% or greater.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4953-4953
Author(s):  
Juan Carlos Ponce Jarquin ◽  
Rosa M. Ayala ◽  
Ana Belen Dueñas Perez ◽  
Daniel Rueda ◽  
María Luisa Martin Ramos ◽  
...  

Abstract Background Acute lymphoblastic leukemia (ALL) is a heterogeneous disease comprising different genetic abnormalities. An increased cytokine receptor-like factor 2 (CRLF2) expression is associated with activating the JAK-STAT pathway and activation and leukemia initiation. Several studies have shown that some first events are insufficient to cause the development of ALL and other genetic changes are required. In 60% of cases, the altered genes are involved in lymphoid maturation (PAX, IKZF1, EBF, LEF1, BTALA/CD200, TOX), cell cycle control and tumour suppression (CDKN2A/B, PTEN, RB), or transcription factors and coactivators (ETV6, ERG, TBL1XR1). But the prognostic significance of deregulated CRLF2 mRNA expression in patients with CNA in the genes previously mentioned is not fully identified. Aims To analyze the frequency and prognostic significance of deregulated expression of  CRLF2 and the copy number alterations (CNA) in EBFF1, IKZF1, JAK2, CDKN, PAX, ETV, BTG1 and RB in a series of ALL patients enrolled in BFM, SHOP or PETHEMA clinical trials. Methods Bone Marrow samples at diagnosis from 69 ALL patients treated in Hospital Universitario 12 de Octubre, between January 2001 and December 2012, were studied by Multiplex ligation- dependent probe amplifications (MLPA) method was used to detect deletions or duplications of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1 and CDKN2A-CDKN2B genes (SALSA MLPA kit P335-B1 ALL-IKZF1; MRC- Holland). Raw data was analyzed using Coffalyzer software (MRC-Holland) Results The median age was 22 years (0.9-88), 40 (58%) male and 29 (42%) female, median WBC count 70,753 x109/L (1,000 – 633,780). B-ALL subtype in 64 cases (92%) and T-ALL subtype in 5 cases (8%). Cytogenetics: 10 normal (14.5%), 16 hyperdiploid (20,5%), 8 t(9;22)(10.3%),4 cases 11q23/MLL (5.1%), and 24 (30.8%) with  other translocations or deletions and no growth (23.1%).  Cytogenetics risk was favourable in 25 cases (26.6%), intermediate in 10 cases (10.6%) and poor in 25 cases (26.6%). CRLF2 expression and CAN results are shown in table 1. CRFL2 over expression was found in 18 cases (23%), it was associated with deletions of IKZF1 (p0.013). Deletions of CDNK were associated with T-ALL subtype (p0.049) and with a tendency to deletions TEL group (p0.081). Deletions of PAX were associated with JAK2 deletions (p0.027) and with a tendency to IKZF1 deletions (p0.064). Rb deletions were associated with ph+ ALL (p0.001) and it had a tendency to the risk of death. Other molecular alterations found were gains of gen EBF 2 (2.6%), IKZF 2 (2.6%), CDKN 4 (5.1%), PAX 5(6.4%), BTG   2 (2.6%), RB 2 (2.6%). There was no association between hyperdiploid karyotype and any of the gene gains analyzed. Regarding survival, CDKN deletions 2A/ B were associated with decreasing of progression free survival P (0.051), independent of the presence of Ph chromosome. Deletions of IKZF1 showed an increased risk of death (p0.011) and tendency for deletions of PAX (p0.064). Conclusions Our findings are consistent with those of other published series. CDKN deletions 2A / B were associated with a decreased progression free survival, independent of the presence of Ph chromosome as described in other series. RB deletions are associated with ph + and have not been described previously, but these findings must be confirm with additional studies. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2005 ◽  
Vol 105 (12) ◽  
pp. 4752-4758 ◽  
Author(s):  
Jose Claudio C. Rocha ◽  
Cheng Cheng ◽  
Wei Liu ◽  
Shinji Kishi ◽  
Soma Das ◽  
...  

Abstract Acquired genetic characteristics of acute lymphoblastic leukemia (ALL) cells are used to individualize therapy, whereas germ line genetic characteristics generally are not. We determined whether ALL outcome was related to 16 genetic polymorphisms affecting the pharmacodynamics of antileukemic agents. Of 246 children, 116 were treated on the lower-risk (LR) and 130 on the higher-risk (HR) arms of a St Jude protocol. Patients in the HR group with the glutathione S-transferase (GSTM1) nonnull genotype had greater risk of hematologic relapse (P = .03), which was further increased by the thymidylate synthetase (TYMS) 3/3 genotype (P = .03). These genotypes remained predictive in multivariate analyses (P &lt; .001 and .003, respectively). No genotypes were predictive in the LR arm. Expression of these 2 genes in ALL blasts was lower in those with low-activity genotypes. For central nervous system relapse, among the HR group, the vitamin D receptor start site (P = .02) and intron 8 genotypes (P = .04) predisposed, whereas for LR patients the TYMS 3/3 genotype predisposed (P = .04). The GSTM1 non-null and TYMS 3/3 genotypes are plausibly linked to drug resistance. Polymorphisms interact to influence antileukemic outcome and represent determinants of response that can be used to optimize therapy. (Blood. 2005;105:4752-4758)


Leukemia ◽  
2021 ◽  
Author(s):  
Greta Winter ◽  
Renate Kirschner-Schwabe ◽  
Stefanie Groeneveld-Krentz ◽  
Gabriele Escherich ◽  
Anja Möricke ◽  
...  

Blood ◽  
1993 ◽  
Vol 81 (10) ◽  
pp. 2488-2491 ◽  
Author(s):  
JV Melo ◽  
DE Gordon ◽  
A Tuszynski ◽  
S Dhut ◽  
BD Young ◽  
...  

Abstract We have previously shown that the chimeric gene ABL-BCR, formed on the derivative chromosome 9q+ as a result of the t(9;22) translocation, is transcriptionally active in 65% of chronic myeloid leukemia patients. We have now used the same technique, reverse transcription/polymerase chain reaction amplification of ABL-BCR transcripts, to study nine patients with Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL); seven expressed the P190 and two the P210 type of BCR- ABL fusion protein. All seven patients with P190 had ABL-BCR transcripts containing a junction between ABL exon Ib and BCR exon 2 (Ib-e2); in two cases, ABL-BCR transcripts with the Ia-e2 junction type were also present. Of the two P210 ALL patients, one had a Ib-b4 ABL- BCR transcript and the other showed no detectable ABL-BCR expression. Although the BCR-ABL gene is probably fundamental in the pathogenesis of the Ph+ leukemias, differential expression of the ABL-BCR gene could contribute to the biologic heterogeneity of the disease.


Blood ◽  
2006 ◽  
Vol 109 (8) ◽  
pp. 3189-3197 ◽  
Author(s):  
Anthony V. Moorman ◽  
Christine J. Harrison ◽  
Georgina A. N. Buck ◽  
Sue M. Richards ◽  
Lorna M. Secker-Walker ◽  
...  

Abstract Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies. However, its usefulness in adult acute lymphoblastic leukemia (ALL) is generally limited to the presence of the Philadelphia (Ph) chromosome because of the low incidence of other recurrent abnormalities. We present centrally reviewed cytogenetic data from 1522 adult patients enrolled on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. The incidence and clinical associations for more than 20 specific chromosomal abnormalities are presented. Patients with a Ph chromosome, t(4;11)(q21;q23), t(8;14)(q24.1;q32), complex karyotype (5 or more chromosomal abnormalities), or low hypodiploidy/near triploidy (Ho-Tr) all had inferior rates of event-free and overall survival when compared with other patients. In contrast, patients with high hyperdiploidy or a del(9p) had a significantly improved outcome. Multivariate analysis demonstrated that the prognostic relevance of t(8;14), complex karyotype, and Ho-Tr was independent of sex, age, white cell count, and T-cell status among Ph-negative patients. The observation that Ho-Tr and, for the first time, karyotype complexity confer an increased risk of treatment failure demonstrates that cytogenetic subgroups other than the Ph chromosome can and should be used to risk stratify adults with ALL in future trials.


Sign in / Sign up

Export Citation Format

Share Document